Drug Profile
Research programme: G-protein coupled receptor modulators - Anchor Therapeutics
Alternative Names: ATI-2341Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Tufts-New England Medical Center
- Developer Anchor Therapeutics; Johnson & Johnson Innovative Medicine; Novartis
- Class Lipopeptides; Small molecules
- Mechanism of Action CXCR4 receptor agonists; G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders; Endocrine disorders; Gastrointestinal disorders; Inflammation; Metabolic disorders; Pain
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA